News | October 25, 2025
Syngene International expands capabilities with new bioconjugation suite in Bengaluru
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Purpose-built bioconjugation facility in Lonza’s Ibex Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
Subscribe To Our Newsletter & Stay Updated
